A Tuft Cell-Like Signature Is Highly Prevalent in Thymic Squamous Cell Carcinoma and Delineates New Molecular Subsets Among the Major Lung Cancer Histotypes.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
06 2021
Historique:
received: 26 07 2020
revised: 23 01 2021
accepted: 06 02 2021
pubmed: 21 2 2021
medline: 8 7 2021
entrez: 20 2 2021
Statut: ppublish

Résumé

In-depth genomic characterization of thymic epithelial tumors (TETs), comprising thymomas and thymic carcinomas (TCs), failed to identify targetable mutations and suggested unique biology of TETs, including KIT expression in most TCs. Recently, tuft cell-like medullary thymic epithelial cells were identified in the murine thymus, and our reanalysis of the published gene expression data revealed that these cells express KIT. In addition, recently, a minor subset of SCLCs with tuft cell-like features was described. We interrogated mRNA expression data from our tumor cohorts (N = 60) and publicly available, independent data sets from TETs and NSCLC (N = 1199) for expression of tuft cell genes and KIT. Expression of KIT and of POU2F3 protein, the master regulator of tuft cells, was analyzed in cancer tissue (N = 344) by immunohistochemistry. Normal human thymic tuft cells and most TCs coexpressed KIT and known tuft cell genes, particularly POU2F3 and GFI1B. Unexpectedly, small subsets of tuft cell-like tumors coexpressing POU2F3, GFI1B, and KIT were also identified among pulmonary squamous cell carcinomas, adenocarcinomas, and large cell neuroendocrine carcinoma and clustered together in each histologic cohort. In addition to the tuft cell-like signature, both thymic and lung tuft cell-like carcinomas had distinct genetic, pathologic, and clinical features in each cohort. We suggest that the tuft cell-like phenotype defines novel subsets of thymic and pulmonary carcinoma. Its high prevalence in thymic squamous cell carcinomas that have no known toxic or viral etiologies suggests a new mechanism of carcinogenesis that may lead to specific drug susceptibilities.

Identifiants

pubmed: 33609752
pii: S1556-0864(21)01708-1
doi: 10.1016/j.jtho.2021.02.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1003-1016

Informations de copyright

Copyright © 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Auteurs

Yosuke Yamada (Y)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan. Electronic address: yyamada@kuhp.kyoto-u.ac.jp.

Katja Simon-Keller (K)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Djeda Belharazem-Vitacolonnna (D)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Hanibal Bohnenberger (H)

Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.

Mark Kriegsmann (M)

Institute of Pathology, Heidelberg University, Heidelberg, Germany.

Katharina Kriegsmann (K)

Department of Hematology, Oncology and Rheumatology, Heidelberg University, Heidelberg, Germany.

Gerhard Hamilton (G)

Department of Surgery, Medical University of Vienna, Vienna, Austria.

Thomas Graeter (T)

Thoracic Surgery, Klinik Löwenstein, Löwenstein, Germany.

Gerhard Preissler (G)

Thoracic Surgery, Klinik Schillerhöhe, Robert-Bosch-Krankenhaus, Gerlingen, Germany.

German Ott (G)

Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany; Dr. Margarete-Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.

Eric Dominic Roessner (ED)

Division of Thoracic Surgery, Academic Thoracic Center Mainz, University Medical Center, Johannes Gutenberg University, Mainz, Germany.

Ilona Dahmen (I)

Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.

Roman K Thomas (RK)

Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Cologne, Germany.

Philipp Ströbel (P)

Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, Germany.

Alexander Marx (A)

Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH